Preclinical and clinical evidence suggests that pancreatic cancer KRAS G12D mutations may confer sensitivity to KRAS G12D-targeted, T-cell-receptor-based adoptive cell therapy, KRAS G12D small-molecule inhibitors, or SOS1 inhibitors [33]. This evidence concerns the gene KRAS and pancreatic neoplasm.